Statement by the Independent Committee of the Board of Directors of Wilson Therapeutics in relation to the public offer from Alexion
The Independent Committee of the Board of Directors of Wilson Therapeutics unanimously recommends that shareholders accept Alexion’s public offerBackgroundThis statement is made by the Independent Committee[1] of the Board of Directors of Wilson Therapeutics AB (publ) (“Wilson Therapeutics”) (the “Committee”) pursuant to Rule II.19 of the Nasdaq Stockholm Takeover Rules (the “Takeover Rules”). Alexion Pharmaceuticals, Inc., a company incorporated in the State of Delaware, United States, and whose shares are listed on NASDAQ under the symbol “ALXN” in United States (“Alexion”), has